Barghout, who led Recor when it won FDA approval of the first renal denervation treatment for hypertension, is the new president of Medtronic’s Interventional Cardiology Therapies business.
Barghout, who led Recor when it won FDA approval of the first renal denervation treatment for hypertension, is the new president of Medtronic’s Interventional Cardiology Therapies business.